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Available online 16 August 2016This study explores the V600BRAF-MITF-PGC-1α axis and comparesmetabolic and functional changesoccurring in
primary and metastatic V600BRAF melanoma cell lines.
V600BRAF mutations in homo/heterozygosis were found to be correlated to high levels of pERK, to downregulate
PGC-1α/β, MITF and tyrosinase activity, resulting in a reduced melanin synthesis as compared to BRAFwt
melanoma cells. In this scenario, V600BRAF switches on a metabolic reprogramming in melanoma, leading to a
decreased OXPHOS activity and increased glycolytic ATP, lactate, HIF-1α and MCT4 levels. Furthermore, the
induction of autophagy and the presence of ER stress markers in V600BRAF metastatic melanoma cells suggest that
metabolic adaptations of these cells occur as compensatory survival mechanisms. For the first time, we underline
the role of peIF2α as an important marker of metastatic behaviour in melanoma.
Our results suggest the hypothesis that inhibition of the glycolytic pathway, inactivation of peIF2α and a
reduction of basal autophagy could be suitable targets for novel combination therapies in a specific subgroup
of metastatic melanoma.
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The study of molecular pathways involved in metastatic melanoma
(MM) is challenging, andmany routes havebeen reported to support pro-
liferation and survival.Mutations in the BRAFgenehave been identified in
50–70% of malignant melanomas. All the mutations occur within the ki-
nase domain, and the specific mutation V600BRAF (V600E, V600K,
V600R and V600D) accounts for approximately 90% of them. This muta-
tion introduces a conformational change in the BRAF activation domain,
which results in the constitutive activation of the protein and a major in-
crease in its basal kinase activity. The RAS-RAF-MEK-ERK pathway plays a
crucial role in regulating gene expression and cell proliferation, contribut-
ing both to melanoma formation and to progression [1].
ERK proteins, through the activation of p90RSK kinase, induce the
phosphorylation of the Microphthalmia-associated transcription factor
(MITF), increasing its activity, but undermining its intracellular
stability. MITF, a master regulator of melanocyte development and
melanomagenesis, [2] binds theMbox in the tyrosinase promoter region,
positively regulating tyrosinase and tyrosinase related protein 1/2 (TRP1/
2) gene expression and thereby increasing melanogenesis [3].
MITF expression is also increased following Adenylate Cyclase (AC)
stimulation induced by the α-MSH hormone [4]. In turn, the cAMP and
Table 1
Genotyping analysis of BRAF, NRAF and MC1R in melanoma cells lines through direct se-
quencing or next generation sequencing.
Cell line Origin MC1R NRAS BRAF exon 15
HBL Metastasis WT/WT WT/WT WT/WT
LND1 Metastasis WT/WT WT/WT WT/WT
hmel1 Metastasis WT/WT WT/WT V600K/WT
M3 Metastasis D184H/D184H WT/WT V600E/V600E
hmel 9 Primary melanoma T314T/WT WT/WT V600R/V600R
hmel 11 Primary melanoma T314T/WT WT/WT V600R/WT
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ogy and stimulatemelanogenesis, and their interplay is essential forMITF
activity [5,6].
Another important pathway in melanocytes and melanoma
development is theWNT/β-catenin signaling. Its activation, determined
by Wnt glycoprotein family members binding to the Frizzled receptors
leads to β-catenin activation as a transcription factor and increases
C-Myc, PPAR1 and CyclinD1 expression [7].
In addition, ERK activation, constitutive in V600BRAF mutated
melanoma cells, determines an induction of cyclin D1 expression
through the activation of the AP1 and ets-2 expression factors [8–12].
In turn cyclin D1, binding CDK4, represses peroxisome proliferator-
activated receptor γ coactivator 1 alpha (PGC-1α) by phosphorylation,
reducing its activity as a transcriptional coactivator [13].
In our study, in particular, attention has been focused on the role of
oxidative phosphorylation (OXPHOS), known to be controlled bymem-
bers of the PGC-1 coactivators family: PGC-1α and PGC-1β. The role of
these proteins has been previously studied in metabolic alterations in
breast and colon cancers [14–16]. PGC-1α, the most closely studied, is
the main positive regulator of mitochondrial biogenesis, increasing the
capacity for cellular energy production [17,18].
Although some of its functions overlap with PGC-1α, less is known
about PGC-1β, that shows distinct functions in different tissues [19,
20]. PGC-1α expression can be influenced by several signalingpathways
and has been involved in angiogenesis development [21]. Recently, an
important role of PGC-1α has been associated to melanoma resistance
to anti-BRAF therapies, and its overexpression, driven by MITF in mela-
noma cells, influences metabolic homeostasis [22–24].
Several decades ago, OttoWarburg observed that cancer cells show a
significantly higher glycolytic activity compared to normal cells even in
the presence of an adequate oxygen supply [25]. This phenomenon
occurs in normal proliferating and tumor cells [26,27], in order to pro-
vide building blocks for the synthesis of new macromolecules such as
proteins, lipids and nucleic acids. Moreover, in melanoma development
and progression, both autophagy and ER stress play an important role in
energy regulation, although their true impact is still unclear [28].
Autophagy is the main process for bulk degradation and recycling of
damaged intra-cellular components [29–31], providingnutrients during
stress conditions, such as nutrient deprivation [32]. Autophagy activa-
tion is frequently observed in late stage malignancy. A deregulation of
autophagy seems to be a secondary event contributing to melanoma
progression, and to play an important role in chemoresistance. Likewise,
ER stress may represent a key event in melanoma development. It is ac-
tivated by the accumulation of unfolded proteins, protein overload or a
depletion of ER calcium stores. It is mediated by specific signaling path-
ways, in order to maintain ER homeostasis promoting the induction of
an Unfolded Protein Response (UPR), ensuring a cytoprotective and
pro-survival activity [28]. Furthermore, a persistent ER stress condition
may induce apoptosis [33].
In this study we analyse the V600BRAF-MITF-PGC-1α axis and com-
paremetabolic and functional changes, autophagy and ER cellular stress
occurring in melanoma cell lines harboring BRAF mutations. In particu-
lar, we focus on gaining a better understanding of relevant pathways
and their correlation in order to develop new approaches for clinical
therapeutic strategies.
2. Materials and methods
2.1. Cell lines
Melanoma cells, hmel1, M3, hmel9, and hmel11, were obtained from
human sporadic melanoma biopsy specimens, after obtaining informed
consent, and genotyped for NRAS, BRAF and MC1R [34,35] (Table 1).
hmel1 and M3 arise from metastases while hmel9 and hmel11 arise
from primary lesions. Melanoma cells HBL, used as control for the
experiments, and LND1, both BRAFwt, were a gift from Prof. G. Ghanem,Université de Bruxelles, Belgium. Cell culture media used was high-
glucose Dulbecco's modified Eagle's medium (DMEM) supplemented
with 10% (v/v) fetal bovine serum (FBS), 1% (v/v) L-glutamine, 1% (v/v)
penicillin/streptomycin, at 37 °C in a humidified atmosphere at 5% CO2.2.2. Tyrosine hydroxylase (TH) activity
Tyrosinase, as tyrosine hydroxylase (TH) activity, was assessed in
cell lysates prepared as described in [34]. The tyrosine hydroxylase ac-
tivity was determined by a radiometric method. One unit was defined
as the amount of enzyme catalyzing the hydroxylation of 1 μmol of l-
tyrosine/min in presence of a 50 μM concentration of the substrate
and 10 μM L-dopa as cofactor.2.3. Western blot analysis
Total cell proteins (30 μg) were separated on 13% Tris–Tricine SDS-
PAGE according to [36] and transferred onto nitrocellulose membranes.
Western blot analysis was performed using the specified primary anti-
bodies against the: CI-39 kDa subunit, CIV-Cox IV subunit, porin
(Invitrogen), monocarboxylate transporters MCT1 and MCT4 (Santa
Cruz Biotechnology), MITF (Thermo Scientific), eIF2α and peIF2α
(Santa Cruz Biotechnology) according to the manufacturer's suggested
concentrations. Protein loading was assessed by reprobing the blots
with β-actin (Sigma), or Tubulin (Sigma-Aldrich) antibodies. pERK
was determined as described in Zanna et al. [35]. The lipid-conjugated
form of LC3 (LC3 II) localises to the membranes of autophagosomes
and it can be separated from non-conjugated form (LC3 I) by immuno-
blotting, since LC3 II migrates faster than LC3 I due to the extreme
hydrophobicity of LC3 II. For LC3 detection, total cell proteins (45 μg)
were separated on 12% Tris-Glycine SDS–PAGE and transferred onto ni-
trocellulose membranes. Western blot analysis was performed using a
specific antibody against LC3B (Cell Signaling Technology).
The secondary antibodies were anti-rabbit-HRP, anti-mouse-HRP
(Millipore) or anti-Goat IgG (SIGMA A-8919). Proteins were detected
by chemiluminescent LiteAblot reagent (Euroclone) and the signal
was quantified by densitometric analysis using Quantity One-4.4.1
imaging software (Bio-Rad Laboratories).2.4. Cyclic adenosine monophosphate (cAMP) assay
The cAMP levels were determined by the direct cAMP ELISA Kit (Enzo
Life Sciences). The cells were treated in the presence of 10−7 M α-MSH
and 10−5 M forskolin for 30 min, used as a positive control, or DMSO
used as a vehicle. For cAMP assays, the culture medium was removed
and 1 ml of 0.1 M HCl was added to the cell layer, followed by 10 min in-
cubation at 37 °C. The lysed cells were scraped and transferred into
Eppendorf tubes. The samples were centrifuged at 1300 ×g for 10 min.
at 4 °C. The supernatants were used for cAMP measurements using a di-
rect immunoassay kit (AssayDesigns) according to themanufacturer's in-
struction. Measurements were performed on a Victor 2030 multilabel
reader (PerkinElmer) and normalized on protein content.
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Purification of total RNA from fibroblasts was carried out using the
RNeasy Mini Kit (Qiagen), according to the manufacturer's protocol.
One microgram of total RNA was then reverse-transcribed to generate
cDNA for PCR using the I Script cDNA Synthesis Kit (Bio-Rad). q-PCR
on cDNA was performed as previously described [37], using
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and β-actin as
internal control. Relative quantification was performed using the
comparative CT method (ΔΔCT). Validated primers for qRT-PCR were
in Table S1.2.6. Endogenous respiration rates in intact cells
Mitochondrial oxygen consumptionwasmeasured polarographical-
ly with a Clark-type oxygen electrode in a water-jacketed chamber
(Hansatech Instruments, Norfolk, UK), magnetically stirred at 37 °C as
previously described [37].
Cells were grown to 70% confluence and medium was changed the
day before the measurement. Cells were collected by trypsinization and
centrifugation, washed once in TD (0.137 M NaCl, 5 mM KCl, 0.7 mM
Na2HPO4, 25 mM Tris–HCl, pH 7.4), resuspended in the same buffer pre-
viously air equilibrated at 37 °C, and transferred into a polarographic
chamber, at a final concentration of 1 to 3 × 106 cells perml. After the na-
tive endogenousO2 consumption ratewas recorded, dinitrophenol (DNP)
was added at a concentration of 30 μM, followed by 20 nMantimycin A to
inhibit the upstream segment of the respiratory chain.pERK1/2 
HBL  hmel1  M3  
44 kDa 
42 kDa 2.7. Total cellular ATP level
The melanoma cells were grown in T25 flasks. Once the cells were at
75% confluence, the ATP level was measured in untreated and 5 μM
oligomycin-treated cells incubated for 30 min. After incubation the cells
were collectedby trypsinization and centrifugation at 500×g and then re-
suspended in phosphate-buffered saline, pH 7.4. Cellular ATP contentwas
determined using the PerkinElmer “ATPlite” Kit (PerkinElmer) according
to the manufacturer's instructions. Measurements were performed on a
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2.8. Lactate level
Cellswere seeded in 60mmplastic Petri dishes and cultured for 24h.















0.0 2.9. Intracellular ROS level
Quantitative analysis of ROS level was performed using the cell
permeant probe 2′-7′dichlorodihydrofluorescin diacetate (H2DCFDA).
Cells were incubated with 10 μM H2DCFDA in a serum-free medium in
the dark at 37 °C for 30min, collected by trypsinization, washed and re-
suspended in an assay buffer (100 mM potassium phosphate, pH 7.4,
2 mM MgCl2). An aliquot was used for protein determination. The
ROS-dependent oxidation of the fluorescent probe (507 nm excitation
and 530 nm emission wavelength) was measured by a Jasco FP6200
spectrofluorometer, as described in [37].Fig. 1. Phosphorylation protein levels of Erk in wild type and V600BRAF melanoma cells.
Representative Western blot of pERK and ERK levels on whole cell lysates from BRAFwt
(HBL) and V600BRAF (hmel1 and M3) melanoma cells. The other melanoma cells are
reported in Zanna et al. [35]. Bar graph shows quantification by densitometric analysis of
pERK protein bands normalized to ERK, used as loading control. Values are means ± SEM
of three independent experiments; significance was calculated with Student's t-test;
*p b 0.05, **p b 0.005 vs HBL.2.10. Statistical analysis
Data of quantitative measurements are expressed as means ± SEM,
and statistically analyzed with Student's t-test; a p value b 0.05 was set
for statistically significant differences.3. Results
3.1. pERK and cAMP levels in V600BRAF and wt melanoma cells
Table 1 shows the origin of the melanoma cells studied and their
MC1R, NRAS and BRAF exon 15 genotype; some of them were already
described in [34,35]. HBL and LND1 cells were wild type for (gene
analyzed)MC1R, NRAS and BRAF and considered as our control. Instead,
hmel1, M3, hmel9, hmel11 melanoma cells, harboring different
V600BRAF mutations, were the experimental cell lines (Table 1). All
melanoma cells arise from metastases, except hmel9 and hmel11
which were from primary melanoma lesions. The NRAS genotype was
wt in all our analyzed cells.
As previously reported in Zanna et al., [35], we found higher levels of
pERK in all melanoma cells harboring the V600BRAF mutation. In detail,
we found the highest pERK levels in M3 and hmel1 cells, the former
harboring a BRAF mutation V600E in homozygosis, the latter a V600K
in heterozygosis (Fig. 1).
Intracellular cAMP levels activate signaling pathways that finally
induce melanogenesis, maintaining the fine balance between prolifera-
tion and differentiation and playing an essential role duringmelanocyte
or melanoma development. Therefore we measured basal cAMP levels
in the M3 cell line (Fig. 2), in response to NDP-MSH or forskolin
treatment, taking into account the previously reported results [35]. In
particular, we compared three metastatic cell lines: M3 and hmel1
(V600BRAF mutated) with HBL (BRAFwt) (Fig. 2). In accordance with
our previous data [35], cAMP levels in response to NDP-MSH or
forskolin were higher in BRAFwt melanoma cells (HBL) compared to
V600BRAF melanoma cells (M3 and hmel1). Thus, both hmel1 and M3
melanoma cells did not show any significant cAMP activation after
forskolin treatment. Although M3 carries a MC1R variant (Table 1),
cAMP levels after α-MSH or forskolin stimulation were not dissimilar
to those of hmel1 (MC1R wt). These results, in accordance with more


























Fig. 2. Effect of V600BRAF on cAMP levels in total melanoma cell lysates. The graph displays
the basal cAMP levels normalized for the total protein content in HBL, hmel1 and M3
melanoma cells (open bar), in the presence of α-MSH (black bar) or forskolin (grey
bar). The cAMP levels of the other melanoma cells are reported in Zanna et al. [35].
Values are means ± SEM of three independent experiments; significance was calculated



























































Fig. 3. Effect of V600BRAF on MITF protein expression and melanogenic enzyme activity.
(A) Representative Western blot of MITF levels performed on whole cell lysates. Bar
graph shows quantification by densitometric analysis of MITF protein bands normalized
to β-actin, used as loading control. Values, means ± SEM of three independent
experiments, are expressed as percentage of HBL values. (B) Bar graph shows tyrosinase
activity expressed as μUE/mg protein. Values are means ± SEM of three independent
experiments. Significance was calculated with Student's t-test; *p b 0.05, **p b 0.005 vs
HBL. (C) Pellets of wt and V600BRAF melanoma cell lines producing different amounts of
eumelanin.
2713A. Ferretta et al. / Biochimica et Biophysica Acta 1863 (2016) 2710–2718suggest the hypothesis that the V600BRAF mutation could affect cAMP
levels in response to MC1R stimulation.
3.2. Pigmentation parameters: MITF levels and tyrosinase activity
MITF is considered amaster regulator gene for pigment cells, having
an important role as a transcription factor involved in melanocytes
survival, growth and differentiation. MITF levels are also one of the
key players in the phenotypic instability of melanomas [6]. For all
melanoma cells we analyzed MITF expression levels by Western blot
analysis (Fig. 3A) and their tyrosinase activity (Fig. 3B). V600BRAF cells
displayed a significantly lower MITF expression than BRAFwt HBL and
LND1 (Fig. 3A), with MITF values ranging from 30% (hmel1, M3) to
50% (hmel9, hmel11) compared to BRAFwt cells.
A crucial step for melanogenesis in melanoma cells is tyrosinase
activity. This activity resulted significantly higher in the melanoma
cells HBL and LND1 (NRAS, MC1R, BRAFwt), thus correlated to the
pigmented phenotype of their cellular pellets (Fig. 3C).
Moreover, V600BRAFmelanoma cells with lowerMITF levels showed a
reduced (by N50% in hmel9 and hmel11) or even almost absent (hmel1,
M3) tyrosinase activity, compared to the higher levels in BRAFwtmelano-
ma cells.
3.3. Expression levels of PGC-1α and PGC-1β in V600BRAF andwtmelanoma
cells
Recently, a“MITF-PGC-1α axis” has been described, involved in me-
lanocyte development as well as in the transformation to melanoma
[39]. Haq et al. [23] reported a decreased expression of themitochondri-
al master regulator PGC-1α, involved in the regulation of metabolism,
differentiation and cell growth in V600EBRAF cell lines. We investigated
the PGC-1α pathways, focusing on the possible metabolic alterations
in melanoma cells. First of all, we analyzed mRNA levels of PGC-1α
and some of its downstream target genes, directly involved in
mitochondrial biogenesis and activity (Fig. 4). Melanoma cells showed
a very wide difference in PGC-1α expression related to the BRAF status.
A downregulation of this coactivator was found in melanoma cells
harboring V600BRAF (hmel1, M3, hmel9, hmel11), compared to HBLmel-
anoma cells. mRNA levels of TFAM (mitochondrial transcription factor)
and cytochrome c resulted significantly lower in all V600BRAF melanoma
cells, compared to wt cells (HBL, LND1) (Fig. 4A), confirming an altered
PGC-1α activity and transcriptional deregulation of its target genes.
Furthermore, we explored the expression of PGC-1β, a member of
the PGC-1 family. PGC-1β shows a similar trend of PGC-1α expression,
presenting very low levels in all V600BRAF melanoma cells (hmel1, M3,hmel9, hmel11), as compared to BRAFwt melanoma cells (HBL, LND1)
(Fig. 4B).
3.4. Functional analysis of the bioenergetic metabolism in wt and V600BRAF
melanoma cells
Cancer cells need to regulate their metabolic program to fuel several
activities such as unlimited proliferation, resistance to cell death,
invasion and metastasis.
Taking into account the existence of a metabolic reprogramming in
melanoma cells, with an energy production strategy change from
mitochondrial oxidative phosphorylation to cytoplasmic aerobic glycol-
ysis, we analyzed the mitochondrial respiratory function by measuring





























































Fig. 4. PGC-1α expression and transcriptional activity in BRAFwt and V600BRAFmelanoma cells. (A) Semi-qRT-PCR analysis of PGC-1α, its target genes (TFAM, cyt c) and (B) PGC-1βmRNA
levels, normalized to the housekeeping gene GAPDH (ΔΔCT), in BRAFwt (open and filled bars) or V600BRAF melanoma cells (grey bars). Values are mean ± SEM of five independent
experiments performed in duplicate. Significance was calculated with Student's t-test; *p b 0.05, **p b 0.005 vs HBL.
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ly lower in the V600BRAF melanoma cells compared to wt melanoma
cells (HBL, LND1), whereas the maximal DNP-uncoupled respiration
(DNP-uncoupled), in presence of a proton ionophore (Fig. 5B), was sig-
nificantly lower exclusively in the primary melanoma cells (hmel9 and
hmel11), as compared to the other MM cells (HBL, LND1, hmel1, M3).
An important feature emerging from this assay (DNP-uncoupled) is
the mitochondrial reserve capacity, calculated by subtracting the basal
OCR from the DNP-stimulated rate. A lower maximal respiratory
capacity observed in primary melanoma cells (hmel9 and hmel11)
could indicate a decreased substrate availability or a compromised mi-
tochondrial integrity (Fig. 5B). To investigate the relative contribution
ofmitochondrial OXPHOS and of glycolysis toATP production,we deter-
mined the intracellular ATP content in the absence and in the presence
of oligomycin, a specific inhibitor of mitochondrial F1F0-ATP-synthase
(Fig. 5C). In all V600BRAF cells (hmel1, M3, hmel9, hmel11), the basal
ATP levels did not differ significantly as compared to BRAFwtmelanoma
cells (HBL, LND1), but a significant decreasewas observed in presence of
oligomycin (hmel1 25.4 ± 2.8% M3 26.4 ± 1.3% hmel9 23.2 ± 4.3%
hmel11 19.7± 3.2% of total ATP content) compared to BRAFwtmelano-
ma cells (HBL 36.4 ± 7.4%; LND1 40.0 ± 12.2% of total ATP content).
These data support the hypothesis that the defective OXPHOS ATP
production by V600BRAF cells could be compensated by an increased
glycolytic supply. Consistent with the increased glycolytic ATP produc-
tion, we found higher extracellular lactate levels measured in the
culture media of all V600BRAF cells, as reported in Fig. 5D.
To assess whether an altered expression of mitochondrial proteins
could underlie the reduction in the mitochondrial respiratory activity,
we evaluated, by semi-quantitative Western blot analysis, the steady-
state levels of some OXPHOS subunits (Fig. 5E). The results showed a
significant decrease (by about 50%) in the protein expression level of
complex I (CI) and complex IV (CIV) subunits, only in primary
melanoma cells (hmel9 and hmel11) as compared to the HBL cells,
while the mitochondrial outer membrane protein expression (porin)
was significantly lower in all the V600BRAF cells (hmel1: 80 ± 6.7%,
M3: 65 ± 12.2%, hmel9: 54 ± 7.4%, hmel11: 56.9 ± 7.9), compared to
wt melanoma cells (HBL 100 ± % LND1:110 ± 8.8%).
Since mitochondria commonly metabolize oxygen, thereby
producing reactive oxygen species (ROS) as a by-product, we evaluated
ROS levels in all melanoma cells. As shown in Fig. 5F, significantly lower
ROS levels, by about 50%, were observed in primary melanomas cells
(hmel9 and hmel11) compared with MM cells values. These data indi-
cate that during melanoma development in primary and metastatic le-
sions with the V600BRAF mutation status, an early activation of the
BRAF-MEK-ERK pathway occurs, shifting the energy balance through
the inhibition of mitochondrial OXPHOS.
The lactate produced by the enhanced anaerobic glycolysis, de-
scribed in V600BRAF melanoma cells, must be eliminated from cells inorder to avoid a drop in intracellular pH, which could result in cellular
damage. To counteract this effect, HIF-1α, a master-transcriptional acti-
vator for a group of genes involved in cell survival, energy metabolism
and pH regulation [40] induces the expression of monocarboxylate
transporter 4 (MCT4), which mediates lactic acid efflux [40]. In fact, in
V600BRAF melanoma cells, we detected significantly higher HIF-1α
mRNA levels compared to HBL cells (HBL: 1; LND1: 1.2; hmel1: 2.9;
M3: 1.6; hmel9: 2.8; hmel11: 1.5 fold increase) (Fig. 6A). Furthermore,
in these cells, significantly higher levels of MCT4 were observed, in
terms of both mRNA (Fig. 6B) and protein expression (Fig. 6C). No
significant changes were observed in the protein expression of MCT1,
which mediates lactic acid influx, in all V600BRAF melanoma cells
(Fig. 6C).
3.5. V600BRAF results in increased basal autophagy and chronic ER stress
induction
Recent data link oncogenic BRAF-induced chronic ER stress and au-
tophagy [28]. We explored the activation of known pathways linking
these two processes. We determined the basal cell autophagy in mela-
noma cells, performing immunoblot analysis of autophagic markers
LC3. As shown in Fig. 7A, a highly significant increase of the LC3II/LC3I
ratio was detected in all V600BRAF cells, hmel1 (96 ± 49%), M3
(113 ± 40%), hmel9 (122 ± 35%) and hmel11 (197 ± 32%) compared
with HBL, BRAFwtmelanoma cells. These results indicate the accumula-
tion of auto-phagosomes in V600BRAFmelanoma cells. Furthermore, the
detection of ER stress was monitored in wt and V600BRAF cell lines,
comparing the phosphorylation status of eIF2α by Western blotting
analysis. Significantly high levels of p-eIF2α were observed only in
MM V600BRAF cells, hmel1 (163 ± 7.3%) and M3 (139 ± 20%).
Conversely, no significant changeswere observed in primarymelanoma
cells hmel9 and hmel11 as compared with BRAFwt melanoma cells
(Fig. 7B).
4. Discussion
Many studies indicate that severalmelanoma transformations require
constitutive activation of the RAS-RAF-MEK-ERK cascade [1,41]. In fact, in
V600BRAF melanoma cells, we found high levels of ERK phosphorylation,
compared to BRAFwt cell lines. Activation of the ERK pathway is known
to phosphorylate MITF [42], whose expression is regulated by the
cAMP/PKA signaling pathway, via phospho-CREB, leading to a reduced
melanin synthesis and, consequently hypopigmentation [43].
In fact, we observed that all V600BRAF melanoma cells have lower
levels of cAMP after the stimulation assay, revealing an impaired
MC1R coupling to the cAMP pathway, downregulation of MITF
expression, a depressed activity of tyrosinase, a key enzyme in melanin




































































































































































































porin             Complex I        Complex IV  
Fig. 5. Mitochondria functional analysis and bioenergetic metabolism in BRAFwt and V600BRAF melanoma cells. (A) Oxygen consumption rates (OCR) in the presence of endogenous
substrates (basal) and (B) DNP (30 μM)-uncoupling agent (Maximal Respiratory Capacity), measured in intact melanoma cells and expressed as nmol O2/min·106 cells. (C) Total
cellular ATP content measured under basal conditions, (open bar). The oligomycin-insensitive (oligo-INSENSITIVE) ATP contents were determined in cells incubated for 1 h with
oligomycin 5 μM, (filled bar). The oligomycin sensitive (oligo-SENSITIVE) ATP production was calculated by subtracting the oligomycin-insensitive value from the basal ATP content,
(grey bar). Values are the means ± SEM of three independent experiment. (D) The extracellular lactate level was measured in the growth medium 24 h after seeding. Values are
means ± SEM of three independent experiments. (E) Protein expression of Complex I (39 kDa) and Complex IV (Cox IV) respiratory chain subunits and of porin, performed on whole
cell lysates. Bar graph shows quantification by densitometric analysis of mitochondrial protein bands normalized to β-actin, used as loading control. Data, means ± SEM of three
independent experiments, are expressed as percentage of HBL values. (F) The intracellular ROS content was detected by DCF fluorescence in cells loaded with DCFH-DA (10 μM) for
30 min. Values are means ± SEM of three independent experiments. Significance was calculated with Student's t-test; *p b 0.05, **p b 0.005 vs HBL.
2715A. Ferretta et al. / Biochimica et Biophysica Acta 1863 (2016) 2710–2718melanoma cells, ERK activation, involved in the anti-melanogenic
mechanism, lead to MITF and tyrosinase down-regulation, resulting in
a reduction in melanin synthesis.
High levels of ERK phosphorylation, upon nuclear accumulation
of ERK, overexpress cyclin D1, which is required for the growth and
survival of melanoma cells in vitro and in vivo [44,45]. Bhalla et al.
identified PGC-1α as a novel CDK4 substrate and further confirmed
that cyclin D1/CDK4 represses PGC-1α activity [13]. Therefore,
V600BRAF sustains the repression of OXPHOS gene expression by
cyclin D1, via PGC-1α inactivation. In this context, our studyidentifies a pathway by which the oncogenic V600BRAF regulates
the bioenergetic metabolism in melanoma, and it underlines how
metabolic reprogramming is accompanied by a suppression of MITF
and PGC-1α, a major regulator of mitochondrial biogenesis and
function.
Furthermore, our findings show that V600BRAF activation in melano-
ma cells is associatedwithOXPHOS dysfunction and an increased glyco-
lytic ATP and lactate production. The decreased OXPHOS will require a
shift to other sources of energy generation to ensure the maintenance







































































































Fig. 6. Effect of HIF-1α on Monocarboxylate transporter (MCT) expression in BRAFwt and V600BRAF melanoma cells. Semi-qRT-PCR analysis of HIF-1α (A) and MCT4 (B) mRNA levels,
normalized to the housekeeping gene GAPDH, in BRAFwt (open and filled bars) or V600BRAF (grey bars) melanoma cells. Values are means ± SEM of five experiments performed in
duplicate. Significance was calculated with Student's t-test; *p b 0.05, **p b 0.005 vs HBL. (B) Representative Western blot of MCT1 and MCT4 levels performed on whole cell lysates,
from BRAFwt (open and filled bars) and V600BRAF (grey bars) melanoma cells. Bar graph shows quantification by densitometric analysis of MCT1 and MCT4 protein bands normalized
to β-tubulin, used as loading control. Values are means ± SEM of five independent experiments. Significance was calculated with Student's t-test; *p b 0.05, **p b 0.005 vs HBL.
2716 A. Ferretta et al. / Biochimica et Biophysica Acta 1863 (2016) 2710–2718glycolysis” or ‘Warburg effect’ [25], characterized by a reduced TCA
cycle and OXPHOS with the concomitant production of ATP and lactic
acid even in presence of oxygen [46].
It is noteworthy that while significantly lower basal oxygen
consumption rates were observed in all V600BRAF melanoma cells, the
DNP-stimulated rate was lower only in primary melanoma cells (hme9
and hmel11) supporting the hypothesis of a lower reserve capacity.
The shift to glycolysis, confirmed by the increased lactate levels, was
found to be dependent on HIF-1α expression. In cancer cells, HIF-1α
blocked pyruvate dehydrogenase (PDH) activity by activating enzyme
pyruvate dehydrogenase kinase 1 (PDK1) [47–49]. This determines
the fate of pyruvate, that is converted into lactate, instead of entering
into the TCA cycle. This behavior is predominant in V600BRAFmelanoma
cells and contributes to the Warburg effect and to the enhancement of
the malignant phenotype [50,51].
To counteract the increased lactate levels, HIF-1α induces monocar-
boxylate transporter 4 (MCT4), which mediates the lactic acid efflux
required to preserve a normal intracellular pH [40]. In fact, inV600BRAF melanoma cells we found a higher HIF-1α expression, higher
extracellular lactate levels, and increased MCT4 mRNA and protein
levels, compared with BRAFwt cells, confirming the metabolic shift of
these cells. It is known that in hypoxic cancer cells, the large amounts
of exported lactate create an acidic tumor environment, which fosters
cancer cell invasion [52].
It has been reported that the induction of autophagy may represent
an adaptation mechanism for cancer cells exposed to an acidic environ-
ment [53] and, furthermore, that V600BRAF induces senescence trigger-
ing autophagy, possibly by inhibition of the mTOR pathway [54]. In
fact, in our study, we detected the induction of autophagy-related
markers expression (LC3), in V600BRAF melanoma cells as compared to
BRAFwt cells.
We can hypothesize that the described V600BRAF melanoma cells
drive a significant upregulation of autophagy as a compensatory surviv-
al mechanism to counteract apoptotic signals. Metabolic activity and
cell survival are consequently sustained by the recycling of degradation








































































Fig. 7. Autophagy and ER stress in BRAFwt and V600BRAF melanoma cells.
(A) Representative Western blot of LC3-I and LC3-II levels performed on whole cell
lysates. Bar graph shows the LC3-II/LC3I ratio calculated by densitometric analysis of the
protein bands normalized to β-actin, used as loading control. Value, means ± SEM of
five independent experiments are expressed as percentage of the HBL value.
(B) Representative Western blot of eIF2α and peIF2α levels performed on whole cell
lysates. Bar graph shows the peIF2α/eIF2α ratio calculated by densitometric analysis of
the protein bands, using eIF2α as loading control. Value, means ± SEM of three
independent experiments are expressed as percentage of the HBL value. Significance
was calculated with Student's t-test; *p b 0.05, **p b 0.005 vs HBL.
2717A. Ferretta et al. / Biochimica et Biophysica Acta 1863 (2016) 2710–2718damaged organelles to oppose the rapid depletion of intracellular nutri-
ents and a buildup of aggregated proteins and damaged organelles [28].
Corazzari et al. described in a recent paper that autophagy and ER
stress are activated in melanoma cells, having a cytoprotective and
pro-survival activity [28]. Furthermore, it is known that phosphoryla-
tion of the α-subunit of the translation initiation factor eIF2 at serine
51 (peIF2α) is a master regulator of cell adaptation to various forms of
stress, acting as a molecular switch that dictates either cell survival or
death [55].
In our studywe highlight an increase of peIF2α inMMbut not in pri-
mary V600BRAF cells, thus delineating autophagy activation by ER stress
as a pro-survival mechanism in peIF2α-proficient cells (MM V600BRAF
cells). To our knowledge, this is the first report of peIF2α as a marker
of a more aggressive phenotype in melanoma.
In conclusion, the innovative findings of our research strongly
suggest that metabolic pathways, autophagy and ER stress may be
important targets for combination therapies in metastatic melanoma.Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2016.08.007.
Transparency document
The Transparency document associated with this article can be
found, in online version.
Acknowledgements
The authors are grateful to Mary V. Pragnell for language assistance
in the preparation of this manuscript. Dr. Anna Ferretta's work was
sponsored by an IMI (Intergruppo Melanoma Italiano) fellowship.
References
[1] H. Davies, G.R. Bignell, C. Cox, P. Stephens, S. Edkins, S. Clegg, J. Teague, H.
Woffendin, M.J. Garnett, W. Bottomley, N. Davis, E. Dicks, R. Ewing, Y. Floyd, K.
Gray, S. Hall, R. Hawes, J. Hughes, V. Kosmidou, A. Menzies, C. Mould, A. Parker, C.
Stevens, S. Watt, S. Hooper, R. Wilson, H. Jayatilake, B.A. Gusterson, C. Cooper, J.
Shipley, D. Hargrave, K. Pritchard-Jones, N. Maitland, G. Chenevix-Trench, G.J.
Riggins, D.D. Bigner, G. Palmieri, A. Cossu, A. Flanagan, A. Nicholson, J.W.C. Ho, S.Y.
Leung, S.T. Yuen, B.L. Weber, H.F. Seigler, T.L. Darrow, H. Paterson, R. Marais, C.J.
Marshall, R. Wooster, M.R. Stratton, P.A. Futreal, Mutations of the BRAF gene in
human cancer, Nature 417 (2002) 949–954, http://dx.doi.org/10.1038/
nature00766.
[2] T.J. Hemesath, E.R. Price, C. Takemoto, T. Badalian, D.E. Fisher, MAP kinase links the
transcription factor microphthalmia to c-kit signalling in melanocytes, Nature 391
(1998) 298–301, http://dx.doi.org/10.1038/34681.
[3] J.C. García-Borrón, F. Solano, Molecular anatomy of tyrosinase and its related pro-
teins: beyond the histidine-bound metal catalytic center, Pigment Cell Res. Spons.
Eur. Soc. Pigment Cell Res. Int. Pigment Cell Soc. 15 (2002) 162–173.
[4] C. Bertolotto, P. Abbe, T.J. Hemesath, K. Bille, D.E. Fisher, J.P. Ortonne, R. Ballotti,
Microphthalmia gene product as a signal transducer in cAMP-induced differentia-
tion of melanocytes, J. Cell Biol. 142 (1998) 827–835.
[5] N. Dumaz, R. Hayward, J. Martin, L. Ogilvie, D. Hedley, J.A. Curtin, B.C. Bastian, C.
Springer, R. Marais, Inmelanoma, RASmutations are accompanied by switching sig-
naling from BRAF to CRAF and disrupted cyclic AMP signaling, Cancer Res. 66 (2006)
9483–9491, http://dx.doi.org/10.1158/0008-5472.CAN-05-4227.
[6] C. Levy, M. Khaled, D.E. Fisher, MITF: master regulator of melanocyte development
and melanoma oncogene, Trends Mol. Med. 12 (2006) 406–414, http://dx.doi.org/
10.1016/j.molmed.2006.07.008.
[7] K. Marinou, C. Christodoulides, C. Antoniades, M. Koutsilieris, Wnt signaling in car-
diovascular physiology, Trends Endocrinol. Metab. 23 (2012) 628–636, http://dx.
doi.org/10.1016/j.tem.2012.06.001.
[8] K. Balmanno, S.J. Cook, Sustained MAP kinase activation is required for the expres-
sion of cyclin D1, p21Cip1 and a subset of AP-1 proteins in CCL39 cells, Oncogene
18 (1999) 3085–3097, http://dx.doi.org/10.1038/sj.onc.1202647.
[9] H. Aktas, H. Cai, G.M. Cooper, Ras links growth factor signaling to the cell cycle ma-
chinery via regulation of cyclin D1 and the Cdk inhibitor p27KIP1, Mol. Cell. Biol. 17
(1997) 3850–3857.
[10] J.N. Lavoie, G. L'Allemain, A. Brunet, R. Müller, J. Pouysségur, Cyclin D1 expression is
regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK
pathway, J. Biol. Chem. 271 (1996) 20608–20616.
[11] B. Herber, M. Truss, M. Beato, R. Müller, Inducible regulatory elements in the human
cyclin D1 promoter, Oncogene 9 (1994) 1295–1304.
[12] C. Albanese, J. Johnson, G. Watanabe, N. Eklund, D. Vu, A. Arnold, R.G. Pestell,
Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through
distinguishable regions, J. Biol. Chem. 270 (1995) 23589–23597.
[13] K. Bhalla, W.-J. Liu, K. Thompson, L. Anders, S. Devarakonda, R. Dewi, S. Buckley, B.-J.
Hwang, B. Polster, S.G. Dorsey, Y. Sun, P. Sicinski, G.D. Girnun, Cyclin D1 represses
gluconeogenesis via inhibition of the transcriptional coactivator PGC1α, Diabetes
63 (2014) 3266–3278, http://dx.doi.org/10.2337/db13-1283.
[14] G.D. Girnun, The diverse role of the PPARγ coactivator 1 family of transcriptional
coactivators in cancer, Semin. Cell Dev. Biol. 23 (2012) 381–388, http://dx.doi.org/
10.1016/j.semcdb.2012.01.007.
[15] E. Klimcakova, V. Chénard, S. McGuirk, D. Germain, D. Avizonis, W.J. Muller, J. St-
Pierre, PGC-1α promotes the growth of ErbB2/Neu-induced mammary tumors by
regulating nutrient supply, Cancer Res. 72 (2012) 1538–1546, http://dx.doi.org/10.
1158/0008-5472.CAN-11-2967.
[16] X. Wang, C.T. Moraes, Increases in mitochondrial biogenesis impair carcinogenesis
at multiple levels, Mol. Oncol. 5 (2011) 399–409, http://dx.doi.org/10.1016/j.
molonc.2011.07.008.
[17] C. Handschin, B.M. Spiegelman, Peroxisome proliferator-activated receptor gamma
coactivator 1 coactivators, energy homeostasis, and metabolism, Endocr. Rev. 27
(2006) 728–735, http://dx.doi.org/10.1210/er.2006-0037.
[18] D.P. Kelly, R.C. Scarpulla, Transcriptional regulatory circuits controlling mitochondri-
al biogenesis and function, Genes Dev. 18 (2004) 357–368, http://dx.doi.org/10.
1101/gad.1177604.
[19] J. Lin, R. Yang, P.T. Tarr, P.-H. Wu, C. Handschin, S. Li, W. Yang, L. Pei, M. Uldry, P.
Tontonoz, C.B. Newgard, B.M. Spiegelman, Hyperlipidemic effects of dietary
2718 A. Ferretta et al. / Biochimica et Biophysica Acta 1863 (2016) 2710–2718saturated fats mediated through PGC-1beta coactivation of SREBP, Cell 120 (2005)
261–273, http://dx.doi.org/10.1016/j.cell.2004.11.043.
[20] C.Wolfrum,M. Stoffel, Coactivation of Foxa2 through Pgc-1beta promotes liver fatty
acid oxidation and triglyceride/VLDL secretion, Cell Metab. 3 (2006) 99–110, http://
dx.doi.org/10.1016/j.cmet.2006.01.001.
[21] J. Chinsomboon, J. Ruas, R.K. Gupta, R. Thom, J. Shoag, G.C. Rowe, N. Sawada, S.
Raghuram, Z. Arany, The transcriptional coactivator PGC-1alpha mediates
exercise-induced angiogenesis in skeletal muscle, Proc. Natl. Acad. Sci. U. S. A. 106
(2009) 21401–21406, http://dx.doi.org/10.1073/pnas.0909131106.
[22] P. Corazao-Rozas, P. Guerreschi, M. Jendoubi, F. André, A. Jonneaux, C. Scalbert, G.
Garçon, M. Malet-Martino, S. Balayssac, S. Rocchi, A. Savina, P. Formstecher, L.
Mortier, J. Kluza, P. Marchetti, Mitochondrial oxidative stress is the Achilles heel of
melanoma cells resistant to Braf-mutant inhibitor, Oncotarget 4 (2013)
1986–1998, http://dx.doi.org/10.18632/oncotarget.1420.
[23] R. Haq, J. Shoag, P. Andreu-Perez, S. Yokoyama,H. Edelman, G.C. Rowe,D.T. Frederick,
A.D. Hurley, A. Nellore, A.L. Kung, J.A. Wargo, J.S. Song, D.E. Fisher, Z. Arany, H.R.
Widlund, Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF,
Cancer Cell 23 (2013) 302–315, http://dx.doi.org/10.1016/j.ccr.2013.02.003.
[24] F. Vazquez, J.-H. Lim, H. Chim, K. Bhalla, G. Girnun, K. Pierce, C.B. Clish, S.R. Granter,
H.R. Widlund, B.M. Spiegelman, P. Puigserver, PGC1α expression defines a subset of
human melanoma tumors with increased mitochondrial capacity and resistance to
oxidative stress, Cancer Cell 23 (2013) 287–301, http://dx.doi.org/10.1016/j.ccr.
2012.11.020.
[25] O. Warburg, On the origin of cancer cells, Science 123 (1956) 309–314.
[26] M. López-Lázaro, Does hypoxia really control tumor growth? Cell. Oncol. Off. J. Int.
Soc. Cell. Oncol. 28 (2006) 327–329.
[27] M. López-Lázaro, The Warburg effect: why and how do cancer cells activate glycol-
ysis in the presence of oxygen? Anti Cancer Agents Med. Chem. 8 (2008) 305–312.
[28] M. Corazzari, F. Rapino, F. Ciccosanti, P. Giglio, M. Antonioli, B. Conti, G.M. Fimia, P.E.
Lovat, M. Piacentini, Oncogenic BRAF induces chronic ER stress condition resulting
in increased basal autophagy and apoptotic resistance of cutaneous melanoma,
Cell Death Differ. 22 (2015) 946–958, http://dx.doi.org/10.1038/cdd.2014.183.
[29] J.L. Armstrong, M. Corazzari, S. Martin, V. Pagliarini, L. Falasca, D.S. Hill, N. Ellis, S. Al
Sabah, C.P.F. Redfern, G.M. Fimia, M. Piacentini, P.E. Lovat, Oncogenic B-RAF signal-
ing in melanoma impairs the therapeutic advantage of autophagy inhibition, Clin.
Cancer Res. Off. J. Am. Assoc. Cancer Res. 17 (2011) 2216–2226, http://dx.doi.org/
10.1158/1078-0432.CCR-10-3003.
[30] R. Lazova, V. Klump, J. Pawelek, Autophagy in cutaneous malignant melanoma, J.
Cutan. Pathol. 37 (2010) 256–268, http://dx.doi.org/10.1111/j.1600-0560.2009.
01359.x.
[31] X.-H. Ma, S. Piao, D. Wang, Q.W. McAfee, K.L. Nathanson, J.J. Lum, L.Z. Li, R.K.
Amaravadi, Measurements of tumor cell autophagy predict invasiveness, resistance
to chemotherapy, and survival inmelanoma, Clin. Cancer Res. Off. J. Am. Assoc. Can-
cer Res. 17 (2011) 3478–3489, http://dx.doi.org/10.1158/1078-0432.CCR-10-2372.
[32] G.M. Fimia, M. Piacentini, Regulation of autophagy in mammals and its interplay
with apoptosis, Cell. Mol. Life Sci. 67 (2010) 1581–1588, http://dx.doi.org/10.
1007/s00018-010-0284-z.
[33] C. Giampietri, S. Petrungaro, S. Conti, A. Facchiano, A. Filippini, E. Ziparo, Cancer mi-
croenvironment and endoplasmic reticulum stress response, Mediat. Inflamm. 2015
(2015) 417281, http://dx.doi.org/10.1155/2015/417281.
[34] P. Zanna, I. Maida, M.C. Turpin Sevilla, F.C. Susca, R. Filotico, M. Arciuli, N. Cassano,
G.A. Vena, R. Cicero, G. Guida, Molecular characterization of novel melanoma cell
lines, J. Biol. Regul. Homeost. Agents 25 (2011) 239–247.
[35] P. Zanna, I. Maida, C. Grieco, S. Guida, M.C. Turpin Sevilla, S. De Summa, S. Tommasi,
G.A. Vena, R. Filotico, G. Guida, Three novel human sporadic melanoma cell lines:
signaling pathways controlled by MC1R, BRAF and β-catenins, J. Biol. Regul.
Homeost. Agents 27 (2013) 131–141.
[36] H. Schägger, T.A. Link, W.D. Engel, G. von Jagow, Isolation of the eleven protein sub-
units of the bc1 complex from beef heart, Methods Enzymol. 126 (1986) 224–237.
[37] A. Ferretta, A. Gaballo, P. Tanzarella, C. Piccoli, N. Capitanio, B. Nico, T. Annese, M. Di
Paola, C. Dell'aquila, M. De Mari, E. Ferranini, V. Bonifati, C. Pacelli, T. Cocco, Effect ofresveratrol on mitochondrial function: implications in parkin-associated familiar
Parkinson's disease, Biochim. Biophys. Acta 1842 (2014) 902–915, http://dx.doi.
org/10.1016/j.bbadis.2014.02.010.
[38] K.C. Lund, L.L. Peterson, K.B. Wallace, Absence of a universal mechanism of
mitochondrial toxicity by nucleoside analogs, Antimicrob. Agents Chemother. 51
(2007) 2531–2539, http://dx.doi.org/10.1128/AAC.00039-07.
[39] Z.‘’e. Ronai, The masters talk: the PGC-1α-MITF axis as a melanoma energizer,
Pigment Cell Melanoma Res. (2013)http://dx.doi.org/10.1111/pcmr.12090.
[40] N.C. Denko, Hypoxia, HIF1 and glucose metabolism in the solid tumour, Nat. Rev.
Cancer 8 (2008) 705–713, http://dx.doi.org/10.1038/nrc2468.
[41] P.T.C. Wan, M.J. Garnett, S.M. Roe, S. Lee, D. Niculescu-Duvaz, V.M. Good, C.M. Jones,
C.J. Marshall, C.J. Springer, D. Barford, R. Marais, Cancer genome project, mechanism
of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF,
Cell 116 (2004) 855–867.
[42] K.W. Vance, C.R. Goding, The transcription network regulating melanocyte
development and melanoma, Pigment Cell Res. Spons. Eur. Soc. Pigment Cell Res.
Int. Pigment Cell Soc. 17 (2004) 318–325, http://dx.doi.org/10.1111/j.1600-0749.
2004.00164.x.
[43] M. Wu, T.J. Hemesath, C.M. Takemoto, M.A. Horstmann, A.G. Wells, E.R. Price, D.Z.
Fisher, D.E. Fisher, c-Kit triggers dual phosphorylations, which couple activation
and degradation of the essential melanocyte factor Mi, Genes Dev. 14 (2000)
301–312.
[44] E.R. Cantwell-Dorris, J.J. O'Leary, O.M. Sheils, BRAFV600E: implications for carcino-
genesis and molecular therapy, Mol. Cancer Ther. 10 (2011) 385–394, http://dx.
doi.org/10.1158/1535-7163.MCT-10-0799.
[45] J.D. Weber, D.M. Raben, P.J. Phillips, J.J. Baldassare, Sustained activation of
extracellular-signal-regulated kinase 1 (ERK1) is required for the continued expres-
sion of cyclin D1 in G1 phase, Biochem. J. 326 (Pt 1) (1997) 61–68.
[46] D.A. Tennant, R.V. Durán, H. Boulahbel, E. Gottlieb, Metabolic transformation in can-
cer, Carcinogenesis 30 (2009) 1269–1280, http://dx.doi.org/10.1093/carcin/bgp070.
[47] C.V. Dang, G.L. Semenza, Oncogenic alterations of metabolism, Trends Biochem. Sci.
24 (1999) 68–72.
[48] R.J. DeBerardinis, Is cancer a disease of abnormal cellular metabolism? New angles
on an old idea, Genet. Med. Off. J. Am. Coll. Med. Genet. 10 (2008) 767–777,
http://dx.doi.org/10.1097/GIM.0b013e31818b0d9b.
[49] J. Kim, I. Tchernyshyov, G.L. Semenza, C.V. Dang, HIF-1-mediated expression of pyru-
vate dehydrogenase kinase: ametabolic switch required for cellular adaptation to hyp-
oxia, Cell Metab. 3 (2006) 177–185, http://dx.doi.org/10.1016/j.cmet.2006.02.002.
[50] R.G. Jones, C.B. Thompson, Tumor suppressors and cell metabolism: a recipe for can-
cer growth, Genes Dev. 23 (2009) 537–548, http://dx.doi.org/10.1101/gad.1756509.
[51] T. McFate, A. Mohyeldin, H. Lu, J. Thakar, J. Henriques, N.D. Halim, H. Wu, M.J. Schell,
T.M. Tsang, O. Teahan, S. Zhou, J.A. Califano, N.H. Jeoung, R.A. Harris, A. Verma, Pyru-
vate dehydrogenase complex activity controls metabolic and malignant phenotype
in cancer cells, J. Biol. Chem. 283 (2008) 22700–22708, http://dx.doi.org/10.1074/
jbc.M801765200.
[52] R.A. Gatenby, E.T. Gawlinski, A.F. Gmitro, B. Kaylor, R.J. Gillies, Acid-mediated tumor
invasion: a multidisciplinary study, Cancer Res. 66 (2006) 5216–5223, http://dx.doi.
org/10.1158/0008-5472.CAN-05-4193.
[53] M.L. Marino, P. Pellegrini, G. Di Lernia, M. Djavaheri-Mergny, S. Brnjic, X. Zhang, M.
Hägg, S. Linder, S. Fais, P. Codogno, A. De Milito, Autophagy is a protective mecha-
nism for human melanoma cells under acidic stress, J. Biol. Chem. 287 (2012)
30664–30676, http://dx.doi.org/10.1074/jbc.M112.339127.
[54] N. Maddodi, W. Huang, T. Havighurst, K. Kim, B.J. Longley, V. Setaluri, Induction of
autophagy and inhibition of melanoma growth in vitro and in vivo by hyperactiva-
tion of oncogenic BRAF, J. Invest. Dermatol. 130 (2010) 1657–1667, http://dx.doi.
org/10.1038/jid.2010.26.
[55] K. Rajesh, J. Krishnamoorthy, U. Kazimierczak, C. Tenkerian, A.I. Papadakis, S. Wang,
S. Huang, A.E. Koromilas, Phosphorylation of the translation initiation factor eIF2α at
serine 51 determines the cell fate decisions of Akt in response to oxidative stress,
Cell Death Dis. 6 (2015), e1591http://dx.doi.org/10.1038/cddis.2014.554.
